ArticleMicrobial biotechnology2019
One-vector CRISPR/Cas9 genome engineering of the industrial fungus Ashbya gossypii.
Article in Microbial biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Unravelling fungal genome editing revolution: pathological and biotechnological application aspects.Archives of microbiology · 2025Review
- Advances in CRISPR/Cas9-Based Gene Editing in Filamentous Fungi.Journal of fungi (Basel, Switzerland) · 2025Review
- Unlocking Fungal Potential: The CRISPR-Cas System as a Strategy for Secondary Metabolite Discovery.Journal of fungi (Basel, Switzerland) · 2024Review
- Utilization of CRISPR-Cas genome editing technology in filamentous fungi: function and advancement potentiality.Frontiers in microbiology · 2024Review
- An oxidoreductase gene CtnD involved in citrinin biosynthesis in Monascus purpureus verified by CRISPR/Cas9 gene editing and overexpression.Mycotoxin research · 2023Article
- Metabolic engineering of Ashbya gossypii for limonene production from xylose.Biotechnology for biofuels and bioproducts · 2022Article
- New Promoters for Metabolic Engineering ofJournal of fungi (Basel, Switzerland) · 2021Article
- Novel CRISPR-Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives.International journal of molecular sciences · 2021Review
- Applications of CRISPR/Cas9 in the Synthesis of Secondary Metabolites in Filamentous Fungi.Frontiers in microbiology · 2021Review
- Sugar transport for enhanced xylose utilization in Ashbya gossypii.Journal of industrial microbiology & biotechnology · 2020Article
- Sporulation inJournal of fungi (Basel, Switzerland) · 2020Review
- Genomic Edition ofBio-protocol · 2020Article
- Dual sgRNA-directed gene deletion in basidiomycete Ganoderma lucidum using the CRISPR/Cas9 system.Microbial biotechnology · 2020Article
- Production of Vitamin B2 (Riboflavin) by Microorganisms: An Overview.Frontiers in bioengineering and biotechnology · 2020Review
- One-vector CRISPR/Cas9 genome engineering of the industrial fungus Ashbya gossypii.Microbial biotechnology · 2019Article
- CRISPR/Cas9 genome editing technology in filamentous fungi: progress and perspective.Applied microbiology and biotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The filamentous fungus Ashbya gossypii is currently used for the industrial production of vitamin B2. Furthermore, the ability of A. gossypii to grow using low-cost substrates together with the inexpensive downstream processing makes this fungus an attractive biotechnological chassis. Indeed, the production in A. gossypii of other high-added value compounds such as folic acid, nucleosides and biolipids has been described. Hence, the development of new methods to expand the molecular toolkit for A. gossypii genomic manipulation constitutes an important issue for the biotechnology of this fungus. In this work, we present a one-vector CRISPR/Cas9 system for genomic engineering of A. gossypii. We demonstrate the efficiency of the system as a marker-less approach for nucleotide deletions and substitutions both with visible and invisible phenotypes. Particularly, the system has been validated for three types of genomic editions: gene inactivation, the genomic erasure of loxP scars and the introduction of point mutations. We anticipate that the use of the CRISPR/Cas9 system for A. gossypii will largely contribute to facilitate the genomic manipulations of this industrial fungus in a marker-less manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.